Related Experiment Video
Updated: Jan 20, 2026
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
A small molecule autophagy inducer exerts cytoprotection against α-synuclein toxicity
1Molecular Biology and Genetics Unit (MBGU), Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bangalore, India.
The small molecule AGK2 enhances autophagy to clear toxic alpha-synuclein aggregates, offering cytoprotective potential in protein-misfolding disorders like alpha-synucleinopathies.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alpha-synucleinopathies are neurodegenerative diseases characterized by the aggregation and toxicity of alpha-synuclein.
- Understanding modifiers of alpha-synuclein toxicity is crucial for developing therapeutic strategies.
Purpose of the Study:
- To characterize the small molecule AGK2 as a potential therapeutic agent for alpha-synucleinopathies.
- To investigate the mechanism by which AGK2 modulates alpha-synuclein toxicity, focusing on autophagy.
Main Methods:
- Utilized yeast and mammalian cell line models to study alpha-synuclein toxicity.
- Employed autophagy flux analyses to assess the impact of AGK2 on autophagosome and autolysosome formation.
- Investigated the involvement of the mTOR pathway in AGK2-mediated autophagy induction.
Main Results:
- AGK2 was found to enhance autophagy, promoting the clearance of toxic alpha-synuclein aggregates.
- Autophagy flux analyses demonstrated that AGK2 specifically induces autolysosomes.
- AGK2-induced autophagy occurred in a manner independent of the mTOR pathway.
Conclusions:
- AGK2 exhibits cytoprotective effects against alpha-synuclein mediated toxicity in various model systems.
- The autophagy-enhancing and mTOR-independent properties of AGK2 suggest its potential as a therapeutic candidate for alpha-synucleinopathies.
Related Concept Videos
08:24A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
04:37Detecting Neurodegenerative Disease-Associated Protein α-Synuclein Using ELISA
04:49Technique for Intranasal Administration of α-Synuclein Aggregates
07:56Utilizing Time-Resolved Protein-Induced Fluorescence Enhancement to Identify Stable Local Conformations One α-Synuclein Monomer at a Time
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein